发明名称 USE OF SODIUM CHANNEL BLOCKER IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING OPTIC NERVE DEGENERATION ASSOCIATED WITH GLAUCOMA
摘要 A method and composition for altering a plausible sequence of pathological events in retinal ganglion cells associated with glaucoma, the sequence including membrane depolarization, influx of millimolar amounts of Na<+> via non-inactivating Na<+> channels, and the lethal elevation of cell Ca<2+> due to reversal of the Na<+> exchanger. The method includes blocking, by administration of a selected composition, of associated, non-inactivating Na<+> channels in retinal ganglion cells in order to limit Na<+>/Ca<2+> exchange in the retinal ganglion cells and prevent buildup of the Ca<2+> level in the retinal ganglion cells to a lethal level. The results in a method of preventing retinal ganglion cell death, associated with glaucoma, by administering to the optic nerve of a mammal, a compound which blocks the non-inactivating sodium ion channels of the optic nerve. Alternately, said invention relates to a method of preventing optic retinal ganglion cell death in a human by administering to the retinal ganglion cells of said human a compound which blocks the non-inactivating sodium ion channel of the retinal ganglion cells.
申请公布号 WO9843612(A1) 申请公布日期 1998.10.08
申请号 WO1998US05941 申请日期 1998.03.26
申请人 ALLERGAN SALES, INC. 发明人 ADORANTE, JOSEPH, S.
分类号 A61K9/08;A61K9/00;A61K31/428;A61K31/496;A61K45/00;A61P27/06;A61P43/00;(IPC1-7):A61K9/00 主分类号 A61K9/08
代理机构 代理人
主权项
地址
您可能感兴趣的专利